EO

ESMO Open

ESMO Open is the European Society for Medical Oncology's online-only, peer-reviewed open access journal covering all disciplines of oncology, with a focus on innovative clinical and translational cancer research. It publishes medical research and educational content across experimental, translational, diagnostic, and therapeutic areas, including original articles, reviews, editorials, correspondence, brief reports, research letters, clinical assay interpretation, diagnostic test presentations, viewpoint articles, phase I trials, meta-analyses, conference reviews, and ESMO position statements.

Looking to publish in ESMO Open? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 8.3
Quartile Q1
Open Access Type Open
eISSN 2059-7029
Invitation Only No
Cost Range Article Publishing Charge: USD 4310 excluding taxes for all articles; 30% discount for eligible corresponding authors who are members of specified oncology societies.

Submission Instructions

ESMO Open accepts the following article types. Click on an article type to view submission instructions.

Original Articles

Cover Letter Cover Letter requirements are not specified.
Abstract A structured abstract is required. Abstract must be no more than 300 words. Abstract must be structured.
Manuscript Manuscript must be up to 4000 words, excluding the title page, abstract, tables, acknowledgements, contributions, and references. Manuscript must follow the basic structure of abstract, introduction, methods, results, discussion, references, and tables and figures as appropriate. Manuscript must include keywords, 3 to 5 highlights, a competing interests statement, the declarations tool content, and any generative AI disclosure statement in a section titled 'Declaration of Generative AI and AI-assisted technologies in the writing process' before the references.
References References may include up to 100 entries. References must be cited in the text using consecutive superscript Arabic numerals, with the reference list numbered in the order of appearance.
Figures & Tables Figures and tables may total up to 5 tables/illustrations. Captions for figures must be supplied separately, and each illustration must be submitted as a separate file. Figures must include captions and tables must include titles, descriptions, and footnotes.
Reformat to ESMO Open using Livewrite Premium

Review

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required and must be structured. Abstract must be no more than 300 words. Abstract must be structured.
Manuscript Manuscript must be up to 5000 words, excluding the title page, abstract, tables, acknowledgements, contributions, and references. Manuscript must include 3 to 5 highlights, a maximum of 6 keywords, a competing interests statement, completion of the declarations tool, and an AI declaration section before the references if generative AI or AI-assisted technologies were used in writing.
References Reference list may include up to 120 references. References may be in any consistent style at submission, with citations indicated in the text by consecutive superscript Arabic numerals and the reference list numbered in order of appearance.
Figures & Tables Review articles may include up to 5 tables and/or illustrations. Each illustration must be submitted as a separate file, and figure captions must be supplied separately. All figures must include captions and be provided in editable format, and all tables must include titles, descriptions, and footnotes and be submitted as editable text.
Reformat to ESMO Open using Livewrite Premium

Letters To The Editor

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is not required for Letters To The Editor.
Manuscript Letters To The Editor must not exceed 500 words. Letters To The Editor must relate to previously published ESMO Open articles within an appropriate time frame or present interesting practice points, and letters relating to a previous publication should use either the same title as the original article or a summarized version. Manuscripts must include keywords, a competing interests statement, completion of the declarations tool, and an AI disclosure statement in a section entitled 'Declaration of Generative AI and AI-assisted technologies in the writing process' before the references if applicable.
References Letters To The Editor may include a maximum of five references. References must be cited in the text using consecutive superscript Arabic numerals and listed in numerical order. References may be submitted in any consistent style or format at submission, and journal names must be abbreviated according to the List of Title Word Abbreviations.
Figures & Tables Letters To The Editor may include a maximum of one table or figure if necessary. Each illustration must be submitted as a separate file, figure captions must be supplied separately, and source files of figures and tables are required whether or not they are embedded in the text. All figures must include captions and be provided in an editable format, and all tables must be submitted as editable text with titles, descriptions, and footnotes.
Reformat to ESMO Open using Livewrite Premium

Short Communication

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required for Short Communications. Structured abstract must not exceed 200 words. Abstract must be structured.
Manuscript Manuscript must be up to 2000 words, excluding the title page, abstract, tables, acknowledgements, contributions, and references. Manuscript must include keywords, 3 to 5 highlights, a competing interests statement, completion of the declarations tool, and an AI disclosure section at the end of the manuscript before the references if generative AI or AI-assisted technologies were used in writing.
References Short Communications may include up to 20 references. References may be in any consistent style at submission, but in-text citations must use consecutive superscript Arabic numerals and the reference list must be numbered in order of appearance.
Figures & Tables Short Communications may include up to 4 tables and/or illustrations. Illustrations must be submitted as separate files and figure captions must be supplied separately. All figures and tables must be cited in the text, figures must include captions, and tables must include titles, descriptions, and footnotes.
Reformat to ESMO Open using Livewrite Premium

Recent Publications

Effect of prior anti-EGFR therapy and baseline ctDNA profiling on the efficacy of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer: an integrated analysis of TRIUMPH/MyPathway

Y. Matsubara, M. Wakabayashi, W. Okamoto, T. Kato, T. Esaki, K. Kato, Y. Komatsu, T. Masuishi, T. Nishina, H. Bando, T. Misumi, M. Fukui, S. Matsuda, Y. Ikeda, J. Malato, K. Schulze, R. Price, A. Sato, T. Yoshino, Y. Nakamura

10.1016/j.esmoop.2026.107734
View Publication

Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study

T. Hoberstorfer, C.P. Spielvogel, C. Englisch, N. Vladic, S. Nopp, F. Moik, M. Preusser, I. Pabinger, C. Ay

10.1016/j.esmoop.2026.107764
View Publication

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib–fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer

S.-A. Im, K. Kalinsky, K.L. Jhaveri, S. Loibl, N. Turner, C. Saura, P. Schmid, S. Loi, E. Hamilton, N. Karadurmus, S. Wang, A.A. Awan, E.M. Ciruelos, C.-F. Chung, E. Thanopoulou, N. Shankar, S. Lim, Y. Jin, C. Song, D. Juric

10.1016/j.esmoop.2026.107735
View Publication

Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C

M. Tetzlaff, J.M. Taube, G.V. Long, R. Dummer, C. Robert, A.M. Menzies, A. Hill, C. Gaudy-Marqueste, D.C. Portnoy, C. Lebbe, R. Krishnan, J. Xu, M. Fukunaga-Kalabis, C. Krepler, R.A. Scolyer

10.1016/j.esmoop.2026.107699
View Publication

Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies

S.B. Maron, R.-H. Xu, Z.A. Wainberg, S.Y. Rha, Y. Zhang, F. Pietrantonio, S.C.S. Oliveira, Y. Li, M.-H. Chen, K. Korphaisarn, E. Elimova, C.A. Calderon, F.V. Herpe, W.P. Yong, T.M. Dos Santos, M. Tan, K. Isse, R.E. Yanes, K. Shitara

10.1016/j.esmoop.2026.107698
View Publication

Frequently asked questions

How long does it take to publish?

3 days from submission to first decision; 86 days from submission to acceptance.

Reformat to ESMO Open using Livewrite Premium

What are the publication costs?

Article Publishing Charge is USD 4310 excluding taxes for all articles. Eligible corresponding authors who are members of specified oncology societies receive a 30% discount.

Reformat to ESMO Open using Livewrite Premium

Research Topics

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Lung Cancer Research Studies Breast Cancer Treatment Studies Colorectal Cancer Treatments and Studies Cancer Treatment and Pharmacology Lung Cancer Diagnosis and Treatment Radiomics and Machine Learning in Medical Imaging Sarcoma Diagnosis and Treatment Ovarian cancer diagnosis and treatment Economic and Financial Impacts of Cancer PARP inhibition in cancer therapy Gastric Cancer Management and Outcomes Genetic factors in colorectal cancer Diverse Scientific and Economic Studies Cancer Cells and Metastasis Cancer, Hypoxia, and Metabolism CAR-T cell therapy research Immunotherapy and Immune Responses Ferroptosis and cancer prognosis BRCA gene mutations in cancer Pancreatic and Hepatic Oncology Research

Related Journals

JO
Journal of Trace Elements in Medicine and Biology Elsevier BV
CN
Cancer Nanotechnology BioMed Central
UC
Urologic Clinics of North America Elsevier BV
MO
Mechanisms of Ageing and Development Elsevier BV
DA
Digestive and Liver Disease Elsevier BV
BR
Biomarker Research BioMed Central